埃索美拉唑可治疗什么病症呢？

What conditions can be treated? Let's take a look. Esomeprazole Indications: Gastroesophageal reflux disease (GORD) includes the initial and long-term treatment of erosive reflux esophagitis (including erosive esophagitis). It can be used for the long-term maintenance treatment of esophagitis and the prevention of GORD recurrence, as well as the symptomatic treatment of GORD disease. Used in combination with antibiotics to eradicate Helicobacter pylori, treat duodenal ulcers caused by Helicobacter pylori, and prevent the recurrence of Helicobacter pylori-related peptic ulcers.

Esomeprazole powerfully inhibits gastric acid secretion, gastric ulcer, gastric reflux, gastric erosion, gastric pain, gastroptosis, chronic gastritis, duodenal ulcer, anastomotic ulcer, reflux esophagitis, esophageal reflux, gastric MALT lymphoma, early gastric cancer, etc. It has the effect of treating and controlling recurrence, improving and alleviating abdominal pain and other widespread discomfort in the digestive system. It is also used on the gastric mucosa to assist in the elimination of Helicobacter pylori infection in the stomach. The efficacy is 1.6 times that of Omelan.

Esomeprazole is the S-isomer of omeprazole. It reduces gastric acid secretion through a specific targeting mechanism and is a specific inhibitor of proton pumps in parietal cells. The R-isomer and S-isomer of omeprazole have similar pharmacodynamic properties. The site and mechanism of action. Esomeprazole is a weak base, which is concentrated in the high-acid environment of the acid secretion microtubules of parietal cells and converted into an active form, thereby inhibiting the H+/K+-ATPase (proton pump) at this site, inhibiting both basal gastric acid secretion and stimulated gastric acid secretion. 

The safety and effectiveness of esomeprazole treatment have been verified in two trials: a clinical comparative study of esomeprazole and omeprazole in the treatment of reflux esophagitis. The total effective rate of esomeprazole was 97.18%, which was significantly higher than that of omeprazole, which was 84.51%. There was no significant difference in the incidence of adverse reactions. Chen Caiming conducted a cost-effectiveness analysis of omeprazole and esomeprazole in the treatment of duodenal ulcer. The recovery rate of the esomeprazole group was 92.6%, which was higher than that of omeprazole, which was 78.6%. The results proved that it has cost and effectiveness advantages.